List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6349970/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mutational landscape and clonal architecture in grade II and III gliomas. Nature Genetics, 2015, 47, 458-468.	9.4	729
2	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	9.4	659
3	Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	13.7	536
4	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. New England Journal of Medicine, 2015, 373, 35-47.	13.9	508
5	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature, 2019, 565, 312-317.	13.7	476
6	Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3460-3465.	3.3	404
7	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood, 2017, 129, 2347-2358.	0.6	268
8	Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. Science Translational Medicine, 2011, 3, 64ra2.	5.8	231
9	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 2018, 20, 66-77.	0.6	225
10	Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. Journal of Clinical Investigation, 2014, 124, 528-542.	3.9	184
11	Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. Science, 2014, 344, 917-920.	6.0	177
12	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature, 2020, 577, 260-265.	13.7	168
13	Blockade of EGFR improves responsiveness to PD-1 blockade in <i>EGFR</i> -mutated non–small cell lung cancer. Science Immunology, 2020, 5, .	5.6	160
14	Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. Journal of Experimental Medicine, 2011, 208, 2403-2416.	4.2	157
15	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia, 2019, 33, 2867-2883.	3.3	148
16	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nature Communications, 2018, 9, 3649.	5.8	140
17	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	0.6	124
18	Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 195-204.	2.0	113

KEISUKE KATAOKA

#	Article	IF	CITATIONS
19	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Reports, 2017, 19, 1874-1887.	2.9	104
20	Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1274-1281.	9.4	100
21	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	0.6	98
22	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia, 2019, 33, 1687-1699.	3.3	98
23	Regeneration of CD8αβ T Cells from T-cell–Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. Cancer Research, 2016, 76, 6839-6850.	0.4	93
24	Mild hypothermia—a revived countermeasure against ischemic neuronal damages. Neuroscience Research, 1998, 32, 103-117.	1.0	85
25	Landscape and function of multiple mutations within individual oncogenes. Nature, 2020, 582, 95-99.	13.7	79
26	Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. Journal of Controlled Release, 2014, 188, 67-77.	4.8	67
27	A Set of Hox Proteins Interact with the Maf Oncoprotein to Inhibit Its DNA Binding, Transactivation, and Transforming Activities. Journal of Biological Chemistry, 2001, 276, 819-826.	1.6	65
28	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	7.7	65
29	DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nature Communications, 2016, 7, 10924.	5.8	64
30	Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. Blood, 2016, 128, 1614-1624.	0.6	64
31	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood, 2018, 131, 621-635.	0.6	64
32	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
33	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood, 2018, 132, 1507-1518.	0.6	63
34	Genetic alterations in adult Tâ€cell leukemia/lymphoma. Cancer Science, 2017, 108, 1719-1725.	1.7	60
35	The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood, 2014, 123, 2540-2549.	0.6	58
36	A comprehensive characterization of <i>cis</i> -acting splicing-associated variants in human cancer. Genome Research, 2018, 28, 1111-1125.	2.4	56

#	Article	IF	CITATIONS
37	AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood, 2011, 118, 6626-6637.	0.6	54
38	Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. Cancer Discovery, 2020, 10, 836-853.	7.7	51
39	Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma. Blood, 2021, 137, 1491-1502.	0.6	49
40	Ecotropic viral integration site 1, stem cell selfâ€renewal and leukemogenesis. Cancer Science, 2012, 103, 1371-1377.	1.7	46
41	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	0.6	44
42	Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. Journal of the National Cancer Institute, 2017, 109, .	3.0	43
43	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Experimental Hematology, 2015, 43, 849-857.	0.2	40
44	Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Oncogene, 2014, 33, 5028-5038.	2.6	38
45	Pretransplant Predictors and Posttransplant Sequels of Acute Kidney Injury after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 394-400.	2.0	37
46	The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transplant International, 2011, 24, 469-476.	0.8	35
47	Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia, 2016, 30, 2270-2273.	3.3	35
48	De Novo Mutations Activating Germline TP53 in an Inherited Bone-Marrow-Failure Syndrome. American Journal of Human Genetics, 2018, 103, 440-447.	2.6	33
49	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Advances, 2020, 4, 5165-5173.	2.5	33
50	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood, 2020, 136, 684-697.	0.6	32
51	Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer. Cancer Research, 2016, 76, 1814-1824.	0.4	31
52	Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplantation, 2010, 45, 513-520.	1.3	30
53	BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia, 2015, 29, 2248-2256.	3.3	30
54	Variegated RHOA mutations in human cancers. Experimental Hematology, 2016, 44, 1123-1129.	0.2	30

#	Article	IF	CITATIONS
55	Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. Npj Precision Oncology, 2020, 4, 20.	2.3	30
56	ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports, 2018, 10, 1115-1130.	2.3	29
57	Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. Oncogene, 2017, 36, 3300-3311.	2.6	27
58	RNA fusions involving <i>CD28</i> are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. Haematologica, 2018, 103, e360-e363.	1.7	27
59	Molecular pathogenesis of disease progression in MLL-rearranged AML. Leukemia, 2019, 33, 612-624.	3.3	26
60	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Research, 2018, 78, 865-876.	0.4	25
61	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Scientific Reports, 2018, 8, 15855.	1.6	24
62	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplantation, 2021, 56, 2355-2366.	1.3	23
63	Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. Oncotarget, 2017, 8, 107513-107529.	0.8	23
64	Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. Journal of Nuclear Medicine, 2001, 42, 124-9.	2.8	23
65	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. Experimental Hematology, 2014, 42, 816-825.	0.2	22
66	Cranial Computed Tomographic and Electroencephalographic Abnormalities in Children with Post-Hemiconvulsive Hemiplegia. European Neurology, 1988, 28, 279-284.	0.6	21
67	Roles of urokinase type plasminogen activator in a brain stab wound. Brain Research, 2000, 887, 187-190.	1.1	21
68	Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 1719-1727.	1.3	20
69	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	2.3	20
70	Maf and Jun Nuclear Oncoproteins Share Downstream Target Genes for Inducing Cell Transformation. Journal of Biological Chemistry, 2001, 276, 36849-36856.	1.6	19
71	Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell. Leukemia, 2016, 30, 1208-1210.	3.3	19
72	The HTLV-1 viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape. PLoS Pathogens, 2021, 17, e1009919.	2.1	19

KEISUKE KATAOKA

#	Article	IF	CITATIONS
73	Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leukemia and Lymphoma, 2010, 51, 1494-1501.	0.6	17
74	PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. Clinical Cancer Research, 2019, 25, 3589-3601.	3.2	16
75	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer, 2020, 20, 5.	1.1	16
76	Recurrence of primary hyperparathyroidism following spontaneous remission with intracapsular hemorrhage of a parathyroid adenoma. Journal of Bone and Mineral Metabolism, 2008, 26, 295-297.	1.3	15
77	Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome. Cancer Science, 2019, 110, 3358-3367.	1.7	15
78	<i>VAV1</i> mutations contribute to development of T-cell neoplasms in mice. Blood, 2020, 136, 3018-3032.	0.6	15
79	Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. Brain Communications, 2020, 2, fcz048.	1.5	14
80	Heterozygous Dnmt3a Mutation Induces Expansion of Hematopoietic Stem Cell Pool in a Murine Model. Blood, 2015, 126, 2355-2355.	0.6	14
81	Decreased RORC expression and downstream signaling in HTLVâ€1â€associated adult Tâ€cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?. International Journal of Cancer, 2019, 144, 1664-1675.	2.3	13
82	A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. Leukemia, 2018, 32, 839-843.	3.3	12
83	Clinical utility of target captureâ€based panel sequencing in hematological malignancies: A multicenter feasibility study. Cancer Science, 2020, 111, 3367-3378.	1.7	11
84	Species differences in metabolic activation and inactivation of 1-nitropyrene in the liver. Cancer Research, 1991, 51, 3919-24.	0.4	11
85	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Science, 2022, 113, 2763-2777.	1.7	11
86	A Carcinoembryonic Antigen Family cDNA from Mouse Placenta Encoding a Protein with a Rare Domain Composition. Placenta, 2000, 21, 610-614.	0.7	10
87	Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. Bone Marrow Transplantation, 2008, 42, 129-130.	1.3	10
88	Multiple mutations within individual oncogenes. Cancer Science, 2021, 112, 483-489.	1.7	10
89	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	2.6	10
90	Constitutional abnormalities of <i>IDH1</i> combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2017, 64, e26647.	0.8	9

#	Article	IF	CITATIONS
91	Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets. Communications Biology, 2020, 3, 544.	2.0	9
92	Genetic biomarkers for PD-1/PD-L1 blockade therapy. Oncoscience, 2016, 3, 311-312.	0.9	9
93	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 66-72.	0.3	9
94	Screening for genes involved in tissue invasion based on placenta formation and cancer cell lines with low and high metastatic potential. Cancer Letters, 2001, 163, 213-219.	3.2	6
95	Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. Experimental Hematology, 2021, 101-102, 42-48.e11.	0.2	6
96	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. Blood, 2014, 124, 826-826.	0.6	6
97	Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2010, 45, 1631-1637.	1.3	5
98	Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic <i>KRAS</i> . Pediatric Blood and Cancer, 2017, 64, e26496.	0.8	5
99	A Cryptic NUP214-ABL1 Fusion in B-cell Precursor Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2018, 40, e397-e399.	0.3	5
100	Central nervous system ganglioneuroblastoma harboring MYO5A-NTRK3 fusion. Brain Tumor Pathology, 2020, 37, 105-110.	1.1	5
101	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Research, 2020, 44, 101755.	0.3	5
102	Bioactivation of cysteine conjugates of 1-nitropyrene oxides by cysteine conjugate beta-lyase purified from Peptostreptococcus magnus. Applied and Environmental Microbiology, 1995, 61, 3781-3787.	1.4	5
103	Outcome of therapyâ€related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematological Oncology, 2022, 40, 752-762.	0.8	5
104	Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. Neuroscience Letters, 1999, 266, 220-222.	1.0	4
105	PD‣1 expression on tumor or stromal cells of nodal cytotoxic Tâ€cell lymphoma: A clinicopathological study of 50 cases. Pathology International, 2020, 70, 513-522.	0.6	4
106	Expression of telomerase reverse transcriptase in peripheral Tâ€cell lymphoma. Cancer Medicine, 2021, 10, 6786-6794.	1.3	4
107	Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia. Blood, 2014, 124, 253-253.	0.6	4
108	PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without <i>PD-L1</i> 3'-UTR structural variations. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, 62, 106-113.	0.3	4

KEISUKE KATAOKA

#	Article	IF	CITATIONS
109	Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia. Blood Advances, 2019, 3, 761-765.	2.5	3
110	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. Blood Cancer Journal, 2021, 11, 27.	2.8	3
111	Novel mechanism of immune evasion involving PD-L1 in various cancers. Translational Cancer Research, 2016, 5, S928-S929.	0.4	3
112	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	0.6	3
113	Description of longitudinal tumor evolution in a case of multiply relapsed clear cell sarcoma of the kidney. Cancer Reports, 2022, 5, e1458.	0.6	3
114	Interstitial pneumonia associated with progression of myelodysplastic syndrome. International Journal of Hematology, 2009, 89, 718-719.	0.7	2
115	Statistical investigation of the random variations in PIXE hair analysis. International Journal of PIXE, 2015, 25, 73-84.	0.4	2
116	Activation of the phosphatidylinositol-3' kinase pathway and DNA synthesis by a mutant insulin-like growth factor I receptor lacking the NPXY motif. Journal of Endocrinology, 2004, 181, 139-146.	1.2	1
117	Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFRα fusion gene. International Journal of Hematology, 2008, 87, 440-441.	0.7	1
118	Positron emission tomography in the diagnosis and therapeutic monitoring of post-transplant lymphoproliferative disorder after cord blood transplantation. Bone Marrow Transplantation, 2010, 45, 610-612.	1.3	1
119	Fulminant Myocarditis after Allogeneic Bone Marrow Transplantation: Successful Cytomegalovirus Therapy and Mechanical Circulatory Support for Bridge to Recovery. Biology of Blood and Marrow Transplantation, 2010, 16, 129-130.	2.0	1
120	TANSLOCATIONS INVOLVING CD28 ARE RARE IN PERIPHERAL T-CELL LYMPHOMAS. Hematological Oncology, 2017, 35, 164-165.	0.8	1
121	PD-1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T-CELL LYMPHOMA PATIENTS. Hematological Oncology, 2019, 37, 272-273.	0.8	1
122	Enhanced Autophagy Promotes Survival of Peripheral Blast Cells from Murine Acute Myeloid Leukemia. Blood, 2014, 124, 2339-2339.	0.6	1
123	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. Blood, 2014, 124, 75-75.	0.6	1
124	Changes in somatosensory circuits after subcortical infarct in rats. Restorative Neurology and Neuroscience, 1992, 4, 323-330.	0.4	0
125	Preservation of the vulva in stage III squamous cell carcinoma with intra-arterial chemotherapy. International Journal of Clinical Oncology, 1999, 4, 307-310.	1.0	Ο
126	More accurate prognostic prediction in diffuse large B-cell lymphoma: beyond cell-of-origin. Annals of Oncology, 2018, 29, 2284-2286.	0.6	0

8

#	Article	IF	CITATIONS
127	Plasma Brain Natriuretic Peptide Is Associated with Hepatic Veno-Occlusive Disease and Early Mortality After Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 3348-3348.	0.6	0
128	Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 3318-3318.	0.6	0
129	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. Blood, 2010, 116, 838-838.	0.6	0
130	NF-κB/TNF-α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity. Blood, 2012, 120, 654-654.	0.6	0
131	Identification of long-term repopulating hematopoietic stem cells by Evi1. Inflammation and Regeneration, 2013, 33, 175-180.	1.5	Ο
132	Novel Biological Effects and Distinct Patterns of Rhoa Mutations in Adult T-Cell Leukemia/Lymphoma and Angioimmunoblastic T Cell Lymphoma. Blood, 2014, 124, 2215-2215.	0.6	0
133	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	0.6	0
134	Identification of Somatic Mutation Contributing to Chemotherapy Resistance in Acute Myeloid Leukemia. Blood, 2016, 128, 600-600.	0.6	0
135	Gene Expression Profiles and Methylation Analysis in Down Syndrome Related Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4084-4084.	0.6	0
136	Structural Variations Involving Programmed Death Ligands in B-Cell and T-Cell Lymphomas. Blood, 2016, 128, 4105-4105.	0.6	0
137	Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. Blood, 2018, 132, 4371-4371.	0.6	0
138	Functional Roles of <i>DDX41</i> Mutations in the Development of Myeloid Malignancies. Blood, 2021, 138, 150-150.	0.6	0
139	Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool. Experimental Hematology, 2022, 109, 45-54.	0.2	0